{"title":"Designing an immuno-epitope candidate vaccine from (Opa, ProA, ProB, RmpM and BamD) proteins against Neisseria gonorrhoeae and Neisseria meningitides","authors":"Ali Adel Dawood","doi":"10.1016/j.vacun.2024.07.004","DOIUrl":null,"url":null,"abstract":"<div><div>The development of a conventional vaccine against gonococci has been difficult since there are no precise correlates of immune protection and the mechanisms of protective immunity are not yet understood. However, the drop in gonorrhea infections might be attributed to the development of vaccines based on <em>Neisseria meningitidis</em>' outer membrane. The goal of this research was to develop a multi-epitope vaccination utilizing proteins from <em>N. meningitidis</em> and <em>Neisseria gonorrhoeae</em>. A <em>Neisseria</em> Multi-Epitope Vaccine (NMEV), containing Opa, ProA, ProB, RmpM, and BamD, was developed using immunophysicochemical informatics techniques. The vaccine consists of 297 amino acids. Antigenicity and sensitivity to NMEV were evaluated. NMEV generates a substantial amount of immune cells and cytokines. The total quality factor of the NMEV 2D structure is around 91%. The vaccine's safety, effectiveness, and other properties make it an attractive option for in vitro and in vivo testing. The suggested NMEV subunit vaccine has the potential to elicit a strong immune response, necessitating additional in vitro and in vivo studies to eliminate Neisseria infections.</div></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vacunas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1576988724000736","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
The development of a conventional vaccine against gonococci has been difficult since there are no precise correlates of immune protection and the mechanisms of protective immunity are not yet understood. However, the drop in gonorrhea infections might be attributed to the development of vaccines based on Neisseria meningitidis' outer membrane. The goal of this research was to develop a multi-epitope vaccination utilizing proteins from N. meningitidis and Neisseria gonorrhoeae. A Neisseria Multi-Epitope Vaccine (NMEV), containing Opa, ProA, ProB, RmpM, and BamD, was developed using immunophysicochemical informatics techniques. The vaccine consists of 297 amino acids. Antigenicity and sensitivity to NMEV were evaluated. NMEV generates a substantial amount of immune cells and cytokines. The total quality factor of the NMEV 2D structure is around 91%. The vaccine's safety, effectiveness, and other properties make it an attractive option for in vitro and in vivo testing. The suggested NMEV subunit vaccine has the potential to elicit a strong immune response, necessitating additional in vitro and in vivo studies to eliminate Neisseria infections.
期刊介绍:
Sin duda una de las mejores publicaciones para conocer los avances en el campo de las vacunaciones preventivas, tanto en el ámbito de la investigación básica como aplicada y en la evaluación de programas de vacunaciones. Su alta calidad y utilidad la ha llevado a estar indexada en los prestigiosos índices IME y SCOPUS.